Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A G Smith

Showing results (361-370 of 382) with videos related to

Pageof 39
Sort By:
Journal of the American Heart Association|July 3, 2020
Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotopic" Anti-Thrombin Without Prolonged AnticoagulationDaxin Chen, Ke Li, Sam Festenstein, et al.
Human Gene Therapy|November 25, 2003
Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primatesTheodore A G Smith, Neeraja Idamakanti, Jennifer Marshall-Neff, et al.
Biochemical and Biophysical Research Communications|October 12, 2000
Adenosine: A partial agonist of the growth hormone secretagogue receptorR G Smith, P R Griffin, Y Xu, et al.
The Journal of Investigative Dermatology|August 12, 1998
Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor geneF Ichii-Jones, J T Lear, A H Heagerty, et al.
Molecular Cell|August 26, 2004
An atomic resolution model for assembly, architecture, and function of the Dr adhesinsKirstine L Anderson, Jason Billington, David Pettigrew, et al.
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Lancet (London, England)|July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky, S Richards, E Matutes, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2004
Complement regulation at the molecular level: the structure of decay-accelerating factorP Lukacik, P Roversi, J White, et al.
Journal of Medical Genetics|October 26, 2007
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphomaL J Worrillow, A G Smith, K Scott, et al.
Journal of Internal Medicine|December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.
Pageof 39

Showing results (361-370 of 382) with videos related to

Sort By:
Pageof 39
Journal of the American Heart Association|July 3, 2020
Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotopic" Anti-Thrombin Without Prolonged AnticoagulationDaxin Chen, Ke Li, Sam Festenstein, et al.
Human Gene Therapy|November 25, 2003
Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primatesTheodore A G Smith, Neeraja Idamakanti, Jennifer Marshall-Neff, et al.
Biochemical and Biophysical Research Communications|October 12, 2000
Adenosine: A partial agonist of the growth hormone secretagogue receptorR G Smith, P R Griffin, Y Xu, et al.
The Journal of Investigative Dermatology|August 12, 1998
Susceptibility to melanoma: influence of skin type and polymorphism in the melanocyte stimulating hormone receptor geneF Ichii-Jones, J T Lear, A H Heagerty, et al.
Molecular Cell|August 26, 2004
An atomic resolution model for assembly, architecture, and function of the Dr adhesinsKirstine L Anderson, Jason Billington, David Pettigrew, et al.
Leukemia|April 26, 2017
E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271A Natoni, T A G Smith, N Keane, et al.
Lancet (London, England)|July 31, 2007
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trialD Catovsky, S Richards, E Matutes, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 22, 2004
Complement regulation at the molecular level: the structure of decay-accelerating factorP Lukacik, P Roversi, J White, et al.
Journal of Medical Genetics|October 26, 2007
Polymorphic MLH1 and risk of cancer after methylating chemotherapy for Hodgkin lymphomaL J Worrillow, A G Smith, K Scott, et al.
Journal of Internal Medicine|December 8, 2016
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndromeH K G Garelius, W T Johnston, A G Smith, et al.
Pageof 39